Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum

PURPOSE: The purpose of this study was to evaluate the anti-tumor activity and safety of anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with gemcitabine plus platinum (GP) as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). PATIENTS AND...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: Chen, Chen, Zhang, Xuanye, Zhou, Yixin, Fu, Sha, Lin, Zuan, Hong, Shaodong, Zhang, Li
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585779/
https://ncbi.nlm.nih.gov/pubmed/33116890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S275947
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars